Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

Not Applicable

Recruiting

• Conditions: Hereditary Cancer Syndrome; Gynecologic Cancer

• Registration Number: NCT05562778
• Lead Sponsor: Weill Medical College of Cornell University

Brief Summary

In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-09-27
• Study First Submitted QC: 2022-09-27
• Study First Posted: 2022-10-03
• Study Start: 2023-01-15
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-24
• Last Update Posted: 2025-07-28
• Primary Completion: 2026-12
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• 8 years of age or older.
• Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.
• Access to a telephone with texting capacity.
• Has not had prior genetic testing for hereditary cancer syndromes.

Exclusion Criteria

• Under 18 years of age
• Has had previous genetic testing for hereditary cancer syndromes
• Does not read/speak in English
• Does not have access to a phone with texting capabilities

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proportion recommended genetic testing	2 years	The proportion of high-risk patients that are recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.

Secondary Outcome Measures

Name	Time	Method
Facilitator of inequity in the utilization of genetic services	2 years	The specific facilitators of inequity that affect the utilization of genetic testing services, among high-risk patients who decline recommended genetic testing. Examples of these facilitators include patient race, ethnicity, affordability, and social determinants of health. The validated survey known as the Patient Reported Utility (PrU) survey will enable these patients to identify various facilitators that influenced their decision not to complete genetic testing. Specifically, the Patient Reported Utility (PrU) that assesses how useful patients found certain outcomes of their test results, ranking from 1 (not at all useful) to 7 (extremely useful).
Proportion completed recommended genetic testing	2 years	The proportion of high-risk patients who complete recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.
Barriers to genetic testing	2 years	The barriers (as identified through qualitative interviews) to genetic testing among high-risk patients who decline recommended genetic testing.

Trial Locations

Locations (4)

NYP Brooklyn Methodist Hospital; 🇺🇸 Brooklyn, New York, United States

NYP Lower Manhattan Hospital; 🇺🇸 New York, New York, United States

Weill Cornell Medicine; 🇺🇸 New York, New York, United States

NYP Medical Group Queens; 🇺🇸 Queens, New York, United States